EGFR and non-small cell lung carcinoma: The AURA3 phase III trial revealed that the median PFS for osimertinib was significantly longer than that for platinum chemotherapy plus pemetrexed (10.1 vs. 4.4 months; hazard ratio of 0.30 with a 95% confidence interval of 0.23–0.41; P < 0.001) in patients with EGFR mutation–positive NSCLC who acquired T790M and whose disease had progressed during previous EGFR-TKI therapy, indicating that osimertinib should be a new standard treatment for this population [8].